William Allan Corp Purchases 6,173 Shares of Kenvue Inc. (NYSE:KVUE)

William Allan Corp raised its position in Kenvue Inc. (NYSE:KVUE) by 16.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,032 shares of the company’s stock after acquiring an additional 6,173 shares during the period. William Allan Corp’s holdings in Kenvue were worth $940,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of KVUE. Grove Bank & Trust raised its position in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue in the fourth quarter worth $29,000. Riverview Trust Co acquired a new stake in shares of Kenvue during the third quarter worth $30,000. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue during the third quarter valued at $35,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Down 4.6 %

KVUE stock opened at $19.78 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $37.93 billion, a P/E ratio of 35.97, a PEG ratio of 2.05 and a beta of 1.45. The company’s 50-day simple moving average is $21.70 and its 200-day simple moving average is $21.95.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 4.15%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group decreased their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.